Skip to content

Study · Randomized controlled trial · n = 792 · 2025

4 results

Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial.

Verma S, Catarig AM, Houlind K, Ludvik B, Nordanstig J, Rasouli N, Sourij H, Thomas S, Nørgaard SK, Bonaca MP

Journal of the American College of Cardiology31 Aug 2025Cited by 2 (Europe PMC)

PMID40892617 (opens in a new tab)DOI10.1016/j.jacc.2025.08.046 (opens in a new tab)PepBankPUB-40892617
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with peripheral artery disease and type 2 diabetes, semaglutide 1.0 mg improved maximum walking distance at week 52 consistently in females and males.

    In plain wordsIn adults with leg artery disease and type 2 diabetes, semaglutide improved walking distance at 52 weeks in both women and men.

    Peptide
    Semaglutide
    Outcome
    IncreaseMaximum walking distance at week 52 by sex
    Study

    n = 792

    Analysis
    Primary
    Outcome group
    Exercise and physical function · Cardiovascular
    Studied dose
    1.0 mg once weekly · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    At week 52, there was a consistent improvement in MWD across sexes, which favored semaglutide treatment (P-interaction value = 0.65).
    1 context sentence
    Summary · context
    The objective of this study was to describe baseline characteristics, functional status, and therapeutic efficacy of once-weekly semaglutide 1.0 mg between females and males with PAD and T2D as a post hoc analysis from the STRIDE trial.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with peripheral artery disease and type 2 diabetes, semaglutide 1.0 mg showed a consistent trend toward improved maximum walking distance at week 57 in females and males.

    In plain wordsIn adults with leg artery disease and type 2 diabetes, semaglutide showed a trend to better walking distance at 57 weeks in women and men.

    Peptide
    Semaglutide
    Outcome
    IncreaseMaximum walking distance at week 57 by sex
    Study

    n = 792

    Analysis
    Secondary
    Outcome group
    Exercise and physical function · Cardiovascular
    Studied dose
    1.0 mg once weekly · 57 weeksAs given in this study (human).

    Source sentences

    Summary
    At week 57, there was a consistent trend for improved MWD that favored semaglutide treatment for both females and males (P interaction = 0.53).
    1 context sentence
    Summary · context
    The objective of this study was to describe baseline characteristics, functional status, and therapeutic efficacy of once-weekly semaglutide 1.0 mg between females and males with PAD and T2D as a post hoc analysis from the STRIDE trial.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with peripheral artery disease and type 2 diabetes, semaglutide 1.0 mg improved pain-free walking distance at week 52 consistently across sexes.

    In plain wordsIn adults with leg artery disease and type 2 diabetes, semaglutide improved pain-free walking distance in both women and men.

    Peptide
    Semaglutide
    Outcome
    IncreasePain-free walking distance at week 52 by sex
    Study

    n = 792

    Analysis
    Secondary
    Outcome group
    Exercise and physical function · Cardiovascular
    Studied dose
    1.0 mg once weekly · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Improvement in pain-free walking distance was consistent across sexes at week 52 in favor of semaglutide (P interaction = 0.80).
    1 context sentence
    Summary · context
    The objective of this study was to describe baseline characteristics, functional status, and therapeutic efficacy of once-weekly semaglutide 1.0 mg between females and males with PAD and T2D as a post hoc analysis from the STRIDE trial.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with peripheral artery disease and type 2 diabetes, semaglutide 1.0 mg improved PAD-specific quality of life (VascuQoL-6) in both sexes, consistent with the overall trial.

    In plain wordsIn adults with leg artery disease and type 2 diabetes, semaglutide improved disease-specific quality of life in both women and men.

    Peptide
    Semaglutide
    Outcome
    IncreaseVascular Quality of Life Questionnaire-6 score by sex
    Study

    n = 792

    Analysis
    Secondary
    Outcome group
    Exercise and physical function · Cardiovascular
    Studied dose
    1.0 mg once weekly · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Likewise, PAD-specific quality of life (assessed using Vascular Quality of Life Questionnaire-6) improvements with semaglutide in both sexes were consistent with the overall trial.
    1 context sentence
    Summary · context
    The objective of this study was to describe baseline characteristics, functional status, and therapeutic efficacy of once-weekly semaglutide 1.0 mg between females and males with PAD and T2D as a post hoc analysis from the STRIDE trial.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.